Interventional oncology devices market seen reaching $3.5 billion by 2030

The interventional oncology devices market is projected to grow from $2.68 billion in 2026 to $3.5 billion by 2030, driven by rising cancer cases, wider use of minimally invasive therapies and new imaging and ablation tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Rising cancer incidence is increasing demand for devices that can diagnose and treat tumors with less invasive procedures. - The market outlook points to sustained expansion as hospitals and cancer centers shift toward targeted treatment and outpatient care.

What happened: - The interventional oncology devices market is projected to rise from $2.5 billion in 2025 to $2.68 billion in 2026. - The market is forecast to reach $3.5 billion by 2030. - The projected compound annual growth rate is 7.1% from 2025 to 2026 and 7.0% through 2030. - The forecast comes from The Business Research Company’s report, Interventional Oncology Devices Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The company also offers a free sample of the market report and the full interventional oncology devices market report.

The details: - Interventional oncology devices are specialized medical tools used to diagnose and treat cancer through minimally invasive techniques. - The devices target tumors directly through therapies such as ablation and embolization. - The market’s recent growth has been supported by rising cancer rates, wider use of interventional radiology, better imaging technology, more adoption of minimally invasive cancer therapies and more specialized oncology centers. - Future growth is expected to come from demand for targeted cancer treatments, higher investment in precision oncology, outpatient cancer care, broader combination interventional therapies and improvements in ablation and embolization devices. - Cancer prevalence remains a core demand driver because more cases increase the need for early detection, staging, monitoring and treatment management. - The Australian Institute of Health and Welfare reported that cancer diagnoses in Australia increased from 160,570 in 2022 to 164,694 in 2023. - North America held the largest global market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The market’s growth rate is steady rather than explosive, which suggests adoption is widening across both advanced and emerging care settings. - The strongest demand is likely to come from technologies that help clinicians treat more patients with fewer complications and shorter recovery times. - North America’s lead reflects mature healthcare infrastructure, while Asia-Pacific’s growth outlook points to room for faster penetration as cancer care capacity expands.

What's next: - More investment is likely in precision oncology, ablation systems and embolization technologies. - The shift toward outpatient cancer care should keep favoring minimally invasive devices. - The report’s forecast suggests the market will continue expanding through 2030 if cancer incidence and technology adoption stay on the current path.

The bottom line: - Interventional oncology devices are moving deeper into mainstream cancer care, with the market on track to add about $1 billion in value by 2030.